40 citations
,
April 2018 in “Endocrine” This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.
20 citations
,
September 2019 in “Epidemiology and Psychiatric Sciences” This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.
11 citations
,
April 2023 in “Annals of General Psychiatry” This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.
November 2023 in “Frontiers in Neuroendocrinology” This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.
February 2025 in “International Urology and Nephrology” In this study, mild improvements in erectile function, penile sensitivity, and nocturnal erections were observed in male patients with post-drug syndrome following a 16-week treatment targeting the peripheral nerves of the genitalia, but significant symptoms persisted, indicating further research is essential.
